Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07241546 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 5 to 6
    • Eligibility criteria expanded, about 7 words
  2. Trial sites expanded: 2 → 5 locationsv4
  3. Study sites: 1 to 2v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2025 to Mar 30, 2026
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 1 of 3 entries
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Trial Details
NCT Number NCT07241546
Lead Sponsor Arrowhead Pharmaceuticals
Conditions
(from sponsor)		 Asthma
Related terms Asthma
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov